Diabetes

Basal insulin peglispro beats glargine for glycemic control

(HealthDay)—For patients with type 2 diabetes, basal insulin peglispro (BIL) provides better glycemic control than insulin glargine, with increased triglycerides, aminotransferases, and liver fat content, according to a ...

Diabetes

Gender-based differences in glycemic control in T2DM

(HealthDay)—For patients with type 2 diabetes, there are gender-based differences in glycemic control and hypoglycemia after insulin treatment, according to research published in the June issue of Diabetes, Obesity and ...

Diabetes

No increased cancer risk with glargine versus human insulin

(HealthDay)—There is no evidence that patients with diabetes who initiate insulin glargine have a higher risk of cancer than similar patients initiating human neutral protamine Hagedorn (NPH) insulin, according to a study ...

Diabetes

Insulin LY2605541 tops glargine for glycemic control in T1DM

(HealthDay)—For patients with type 1 diabetes, the novel, long-acting basal insulin LY2605541 yields greater improvement in glycemic control compared with insulin glargine, according to a study published online Nov. 27 ...

Diabetes

Insulin glargine's main metabolic effect as metabolite M1

(HealthDay)—For patients with type 2 diabetes, following administration of a subcutaneous injection of a therapeutic dose of insulin glargine, glargine is minimally detectable in blood, and most of the plasma insulin concentration ...

page 2 from 3